Hot Products
Hot products from BioCrick which is a professional high-purity natural products manufacturer are well known to scientists around the world because of their high purity and stability. Each product is a chemical compound or substance produced by a living organism—that is, found in nature. In the broadest sense, natural products include any substance produced by life.Natural products remain the best sources of drugs and drug leads, and this remains true today despite the fact that many pharmaceutical companies have deemphasized natural products research in favor of HTP screening of combinatorial libraries during the past 2 decades. From 1940s to date, 131 (74.8%) out of 175 small molecule anticancer drugs are natural product-based/inspired, with 85 (48.6%) being either natural products or derived therefrom. From 1981 to date, 79 (80%) out of 99 small molecule anticancer drugs are natural product-based/inspired, with 53 (53%) being either natural products or derived therefrom. Among the 20 approved small molecule New Chemical Entities (NCEs) in 2010, a half of them are natural products.
Hot products from the professional high-purity natural products manufacturer
| Cat.No. | Product Name |
|---|---|
| BCC3875 | ZM336372 |
| Potent, selective inhibitor of c-Raf in vitro (IC50 = 70 nM for inhibition of human c-Raf). Shows 10-fold selectivity over B-Raf. Also inhibits SAPK2/p38 (IC50 = 2 μM). Selective over 17 other protein kinases including PKA, PKC, p42 MAPK, CDK1 and SAPK1/JNK (up to 50 μM). Also available as part of the MAPK Cascade Inhibitor. | |
| BCC3890 | Adaphostin |
| p210bcr/abl tyrosine kinase inhibitor (IC50 = 14 μM). Induces apoptosis in T-lymphoblastic human leukemia cell lines (IC50 values range from 16.8 to 216.3 nM) in vitro. Displays selectivity for chronic myelogenous leukemia (CML) myeloid progenitors in vitro. | |
| BCC3893 | 1-Naphthyl PP1 |
| Selective inhibitor of src family kinases v-Src and c-Fyn as well as the tyrosine kinase c-Abl. (IC50 values are 1.0, 0.6, 0.6, 18 and 22 μM for v-Src, c-Fyn, c-Abl, CDK2 and CAMK II respectively). Preferentially inhibits mutant over wild-type kinases (IC50 values are 1.5 vs 1000 nM for I338G v-src and v-src respectively). | |
| BCC3896 | CH 223191 |
| Potent aryl hydrocarbon receptor (AhR) antagonist (IC50 = 30 nM). Exhibits no AhR agonist-like activity (at concentrations up to 100 μM). Inhibits 2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD)-induced AhR-dependent transcription in vitro and reduces TCDD-induced toxicity in vivo. Attenuates Th17 differentiation of naive CD4 T cells and promotes expansion of hematopoietic stem cells in vitro. | |
| BCC3897 | 6,2',4'-Trimethoxyflavone |
| Aryl hydrocarbon receptor antagonist (EC50 = 0.9 μM). Exhibits no short term agonist activity and no species or promoter dependence. | |
| BCC3898 | MeBIO |
| Control analog of 6-bromoindirubin-3'-oxime (BIO). Displays minimal activity against CDK1/Cyclin B, GSK-3 α/β, and CDK5/p25 (IC50 values are 92.0, 44-100 and >100 μM respectively). Aryl hydrocarbon receptor (AhR) agonist; causes redistribution of AhR to the nucleus. | |
| BCC3900 | DiMNF |
| Selective aryl hydrocarbon receptor (AHR) modulator (SAhRM). Suppresses expression of CD55 and CD46 induced by IL-1β in an inflammatory tumor cell microenvironment; exhibits no effect on basal CD55 or CD46 expression. | |
| BCC3916 | DBeQ |
| Selective and reversible inhibitor of p97 ATPase (IC50 = 1.5 μM). Induces executioner caspases (caspase-3 and caspase-7) rapidly. Blocks the degradation of endoplasmic reticulum-associated degradation (ERAD) reporters; also blocks autophagosome maturation and promotes accumulation of LC3-II. | |
